ImmunoGen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $7.77 billion, with shareholders equity totaling $561.60 million.
The company employs approximately 79 people and operates in the Health Care sector, within the Biotechnology industry.
Over the past 12 months, ImmunoGen Inc. reported $237.75 million in revenue, generating net income of $-73.52 million.
Key financial metrics include a P/E ratio of -105.74, a price-to-book (P/B) ratio of 13.84, and a trailing twelve-month dividend yield of 0.00%.
The company trades under the ticker IMGN.